UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of $621.99 million. The enterprise value is $547.95 million.

Market Cap	621.99M
Enterprise Value	547.95M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, before market open.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

UroGen Pharma has 46.11 million shares outstanding. The number of shares has increased by 40.86% in one year.

Current Share Class	46.11M
Shares Outstanding	46.11M
Shares Change (YoY)	+40.86%
Shares Change (QoQ)	+0.83%
Owned by Insiders (%)	5.09%
Owned by Institutions (%)	83.26%
Float	34.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.36
Forward PS	4.58
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.96
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.65

Current Ratio	5.65
Quick Ratio	5.13
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-7.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-29.80%
Return on Invested Capital (ROIC)	-96.25%
Return on Capital Employed (ROCE)	-51.97%
Revenue Per Employee	$390,940
Profits Per Employee	-$589,068
Employee Count	235
Asset Turnover	0.41
Inventory Turnover	1.28

Taxes

In the past 12 months, UroGen Pharma has paid $3.17 million in taxes.

Income Tax	3.17M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.48% in the last 52 weeks. The beta is 0.40, so UroGen Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	-21.48%
50-Day Moving Average	9.36
200-Day Moving Average	10.92
Relative Strength Index (RSI)	64.66
Average Volume (20 Days)	5,839,707

Short Selling Information

The latest short interest is 6.13 million, so 13.28% of the outstanding shares have been sold short.

Short Interest	6.13M
Short Previous Month	3.92M
Short % of Shares Out	13.28%
Short % of Float	17.81%
Short Ratio (days to cover)	1.11

Income Statement

In the last 12 months, UroGen Pharma had revenue of $91.87 million and -$138.43 million in losses. Loss per share was -$3.04.

Revenue	91.87M
Gross Profit	82.39M
Operating Income	-106.86M
Pretax Income	-100.36M
Net Income	-138.43M
EBITDA	-106.58M
EBIT	-106.86M
Loss Per Share	-$3.04

Full Income Statement

Balance Sheet

The company has $195.89 million in cash and $126.36 million in debt, giving a net cash position of $74.04 million or $1.61 per share.

Cash & Cash Equivalents	195.89M
Total Debt	126.36M
Net Cash	74.04M
Net Cash Per Share	$1.61
Equity (Book Value)	-46.46M
Book Value Per Share	-1.01
Working Capital	195.18M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$107.06 million and capital expenditures -$339,000, giving a free cash flow of -$107.39 million.

Operating Cash Flow	-107.06M
Capital Expenditures	-339,000
Free Cash Flow	-107.39M
FCF Per Share	-$2.33

Full Cash Flow Statement

Margins

Gross margin is 89.68%, with operating and profit margins of -116.31% and -150.68%.

Gross Margin	89.68%
Operating Margin	-116.31%
Pretax Margin	-147.23%
Profit Margin	-150.68%
EBITDA Margin	-116.01%
EBIT Margin	-116.31%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-40.86%
Shareholder Yield	-40.86%
Earnings Yield	-22.26%
FCF Yield	-17.27%

Analyst Forecast

The average price target for UroGen Pharma is $23.00, which is 70.50% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$23.00
Price Target Difference	70.50%
Analyst Consensus	Strong Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -3.85 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.85
Piotroski F-Score	2